This protease
activates hepatocyte growth factor (HGF) and urokinase plasminogen activator (uPA), two proteins thought to be involved in the growth and motility of cancer cells, particularly carcinomas, and in the vascularization of tumors.
Leukemic cells can feed themselves through increased secretion
of hepatocyte growth factor (HGF), which then activates its receptor, MET, to promote growth.
Hepatocyte growth factor (HGF)(or scatter factor (SF) pathways - Met inhibitors could be used in combination with other treatment modalities such as; radiotherapy and / or immunotherapy in treatment of cutaneous melanoma.
Cell inhibition is believed to be due to soluble / growth factors like IFN - γ, interleukin [IL]-1 β, Transforming growth factor (TGF)- β1 and
hepatocyte growth factor (HGF) in humans 22.
It is known that many drugs used in the treatment of various types of cancer including melanoma are targeting Met and
hepatocyte growth factor (HGF)(or scatter factor (SF) pathways.
Hepatocyte growth factor (HGF) gene therapy could be used to treat patients with severe peripheral arterial disease (PAD), suggest results...
Hepatocyte growth factor, or HGF, is a cytokine that is released after tissue injury.
Some of the key players in this hormonal symphony are
hepatocyte growth factor and fibroblast growth factor.
Hepatocyte Growth Factor Is a Reliable Marker for Efficient Anti-Bacterial Therapy within the First Day of Treatment